Aprea Therapeutics, Inc.
APRE
$1.40
-$0.05-3.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.13% | -10.73% | 9.30% | -1.67% | 8.35% |
| Total Depreciation and Amortization | 20.67% | 67.97% | 218.57% | 5,575.00% | -69.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.38% | 19.19% | -9.99% | 23.47% | 16.15% |
| Change in Net Operating Assets | 145.53% | 125.38% | -165.20% | -295.30% | 66.14% |
| Cash from Operations | 6.03% | -0.89% | -11.32% | -10.65% | 19.33% |
| Capital Expenditure | 100.00% | 92.58% | 83.35% | 73.57% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 92.58% | 83.35% | 73.57% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.25% | -98.75% | 178.82% | 171.76% | 147.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.02% | 97.51% | -103.21% | -102.22% | -102.03% |
| Cash from Financing | -96.09% | -98.86% | 188.36% | 180.37% | 152.26% |
| Foreign Exchange rate Adjustments | 140.20% | 94.40% | 14.46% | 104.34% | 97.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,303.43% | -1,025.23% | 117.40% | 111.62% | 108.91% |